Logo image of DC4.DE

DEXCOM INC (DC4.DE) Stock Fundamental Analysis

Europe - FRA:DC4 - US2521311074 - Common Stock

61.38 EUR
+0.63 (+1.04%)
Last: 10/24/2025, 7:00:00 PM
Fundamental Rating

6

Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 59 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 is valued quite expensive, but it does show an excellent growth. These ratings would make DC4 suitable for growth investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

DC4 had positive earnings in the past year.
In the past year DC4 had a positive cash flow from operations.
DC4 had positive earnings in each of the past 5 years.
Each year in the past 5 years DC4 had a positive operating cash flow.
DC4.DE Yearly Net Income VS EBIT VS OCF VS FCFDC4.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

DC4's Return On Assets of 7.80% is fine compared to the rest of the industry. DC4 outperforms 79.66% of its industry peers.
With an excellent Return On Equity value of 22.21%, DC4 belongs to the best of the industry, outperforming 91.53% of the companies in the same industry.
DC4's Return On Invested Capital of 14.52% is amongst the best of the industry. DC4 outperforms 94.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is above the industry average of 9.04%.
The last Return On Invested Capital (14.52%) for DC4 is above the 3 year average (11.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROIC 14.52%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DC4.DE Yearly ROA, ROE, ROICDC4.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

Looking at the Profit Margin, with a value of 13.29%, DC4 is in the better half of the industry, outperforming 76.27% of the companies in the same industry.
In the last couple of years the Profit Margin of DC4 has grown nicely.
DC4 has a better Operating Margin (17.22%) than 76.27% of its industry peers.
In the last couple of years the Operating Margin of DC4 has grown nicely.
DC4 has a Gross Margin of 60.01%. This is comparable to the rest of the industry: DC4 outperforms 55.93% of its industry peers.
In the last couple of years the Gross Margin of DC4 has remained more or less at the same level.
Industry RankSector Rank
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DC4.DE Yearly Profit, Operating, Gross MarginsDC4.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DC4 is creating value.
DC4 has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DC4 has more shares outstanding
The debt/assets ratio for DC4 has been reduced compared to a year ago.
DC4.DE Yearly Shares OutstandingDC4.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DC4.DE Yearly Total Debt VS Total AssetsDC4.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 5.05 indicates that DC4 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.05, DC4 belongs to the top of the industry, outperforming 83.05% of the companies in the same industry.
DC4 has a debt to FCF ratio of 4.38. This is a neutral value as DC4 would need 4.38 years to pay back of all of its debts.
DC4 has a better Debt to FCF ratio (4.38) than 61.02% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that DC4 is somewhat dependend on debt financing.
The Debt to Equity ratio of DC4 (0.50) is worse than 61.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Altman-Z 5.05
ROIC/WACC1.84
WACC7.88%
DC4.DE Yearly LT Debt VS Equity VS FCFDC4.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

DC4 has a Current Ratio of 1.52. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a Current ratio of 1.52. This is comparable to the rest of the industry: DC4 outperforms 47.46% of its industry peers.
DC4 has a Quick Ratio of 1.35. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a Quick ratio of 1.35. This is in the better half of the industry: DC4 outperforms 66.10% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.35
DC4.DE Yearly Current Assets VS Current LiabilitesDC4.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

7

3. Growth

3.1 Past

DC4 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.86%.
Measured over the past years, DC4 shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.25% on average per year.
DC4 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.30%.
The Revenue has been growing by 22.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%

3.2 Future

Based on estimates for the next years, DC4 will show a very strong growth in Earnings Per Share. The EPS will grow by 22.60% on average per year.
DC4 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.90% yearly.
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DC4.DE Yearly Revenue VS EstimatesDC4.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
DC4.DE Yearly EPS VS EstimatesDC4.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 41.76 indicates a quite expensive valuation of DC4.
Compared to the rest of the industry, the Price/Earnings ratio of DC4 is on the same level as its industry peers.
DC4's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.91.
The Price/Forward Earnings ratio is 27.08, which means the current valuation is very expensive for DC4.
DC4's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.92. DC4 is around the same levels.
Industry RankSector Rank
PE 41.76
Fwd PE 27.08
DC4.DE Price Earnings VS Forward Price EarningsDC4.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

DC4's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. DC4 is more expensive than 62.71% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DC4 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 48.89
EV/EBITDA 26.02
DC4.DE Per share dataDC4.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

DC4's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of DC4 may justify a higher PE ratio.
DC4's earnings are expected to grow with 24.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.56
PEG (5Y)1.43
EPS Next 2Y26.2%
EPS Next 3Y24.65%

0

5. Dividend

5.1 Amount

DC4 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

DEXCOM INC

FRA:DC4 (10/24/2025, 7:00:00 PM)

61.38

+0.63 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap24.07B
Revenue(TTM)4.30B
Net Income(TTM)571.50M
Analysts84.57
Price Target89.5 (45.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)0.28%
EPS NY rev (1m)0.14%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE 41.76
Fwd PE 27.08
P/S 6.49
P/FCF 48.89
P/OCF 28.25
P/B 10.84
P/tB 11.34
EV/EBITDA 26.02
EPS(TTM)1.47
EY2.39%
EPS(NY)2.27
Fwd EY3.69%
FCF(TTM)1.26
FCFY2.05%
OCF(TTM)2.17
OCFY3.54%
SpS9.46
BVpS5.66
TBVpS5.41
PEG (NY)1.56
PEG (5Y)1.43
Graham Number13.68
Profitability
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROCE 18.43%
ROIC 14.52%
ROICexc 53.56%
ROICexgc 59.66%
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
FCFM 13.27%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Debt/EBITDA 1.33
Cap/Depr 176.58%
Cap/Sales 9.69%
Interest Coverage 250
Cash Conversion 101.12%
Profit Quality 99.88%
Current Ratio 1.52
Quick Ratio 1.35
Altman-Z 5.05
F-Score6
WACC7.88%
ROIC/WACC1.84
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year77.25%
EBIT Next 3Y38.83%
EBIT Next 5Y31.4%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%

DEXCOM INC / DC4.DE FAQ

What is the ChartMill fundamental rating of DEXCOM INC (DC4.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE.


Can you provide the valuation status for DEXCOM INC?

ChartMill assigns a valuation rating of 3 / 10 to DEXCOM INC (DC4.DE). This can be considered as Overvalued.


Can you provide the profitability details for DEXCOM INC?

DEXCOM INC (DC4.DE) has a profitability rating of 8 / 10.


What is the earnings growth outlook for DEXCOM INC?

The Earnings per Share (EPS) of DEXCOM INC (DC4.DE) is expected to grow by 26.84% in the next year.